"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Case report

Right Lower Extremity Osteomyelitis With Alcaligenes faecalis in a Patient With Poorly Controlled Type 2 Diabetes Mellitus


Alcaligenes faecalis (A. faecalis) is a Gram-negative, rod-shaped, oxidase(+) and catalase(+), obligate aerobe commonly found in soil or water. It has also been found in human intestinal microbiota and more rarely in hospital settings and is typically associated with opportunistic infections. Although it has intrinsic resistance to many commonly used antibiotics, it is increasingly found to have developed antibiotic resistance. We present a rare case of A. faecalis osteomyelitis in a patient with a chronic diabetic foot ulcer.


Alcaligenes faecalis (A. faecalis) is a Gram-negative, rod shaped, oxidase(+) and catalase(+), obligate aerobe. It is commonly found in soil or water, but has also been found in human intestinal microbiota. In hospital settings, it is most often found in respirators, dialysis machines, or IV solutions, and is associated with opportunistic infections [1,2]. It is generally resistant to aminoglycosides and tetracyclines and susceptible to trimethoprim/sulfamethoxazole (TMP-SMX) and β-lactam antibiotics such as ureidopenicillins, ticarcillin-clavulanic acid, cephalosporins, and carbapenems [3]. However, recent reports have identified genes responsible for intrinsic resistance to β-lactams antibiotics [4]A. faecalis has been associated with a variety of infections including bacteremia, meningitis, endophthalmitis, otitis media, endocarditis, pneumonia, peritonitis, urinary tract infection, and has been previously documented to cause skin and soft tissue infections including diabetic foot ulcers [5,6]. We present a case of A. faecalis osteomyelitis of the right lower extremity in a patient with a longstanding diabetic foot ulcer.

Case Presentation

A 55-year-old male with a past medical history of tobacco use disorder, daily marijuana use, reported anaphylaxis to penicillins, and insulin-dependent type 2 diabetes mellitus (most recent hemoglobin A1C 6.3%) presented with worsening pain of a chronic wound of the hallux of the right lower extremity that had been present for eight months. The patient had previously followed with wound care after previous surgical debridement, however, had failed to follow up as scheduled and had not been evaluated or treated with antibiotics in more than four months prior to presenting to the emergency department. The patient had received courses of TMP-SMX, and cefuroxime for other infections within 12 months prior to presenting. 

On initial presentation, the patient was hemodynamically stable and afebrile. Physical exam was significant for a full-thickness ulcerative defect in the distal tuft of the right hallux measuring 1.6 x 1.8 x 0.9 cm with seropurulent exudate with erythema and edema involving the entire right hallux. There was no leukocytosis; however, inflammatory markers, C-reactive protein, and erythrocyte sedimentation rate were elevated. X-ray of the right foot revealed soft tissue ulceration of the first digit with fragmentation at the tip of the first distal phalanx, concerning for acute osteomyelitis (Figure 1). The patient received a single dose of IV metronidazole in the emergency department and was subsequently admitted for further evaluation and treatment. MRI demonstrated findings consistent with osteomyelitis involving the distal tip of the first distal phalanx. Podiatry was consulted for surgical debridement and the patient subsequently underwent sequestrectomy of the bone of the distal phalanx of the toe with fillet flap closure with apparent source control. Post-surgical intervention, with new onset of signs concerning for sepsis, the patient was initiated on empiric antibiotics pending intraoperative cultures with vancomycin and meropenem. The postoperative course was uneventful and the patient remained afebrile without leukocytosis. Intraoperative wound cultures grew Streptococcus pyogenes. Sensitivity for the Streptococcus pyogenes was obtained showing sensitivity to amoxicillin/clavulanic acid. In the setting of clinical improvement and with no signs of systemic infection and no further organisms isolated, the decision was made to discharge the patient on postoperative day three with oral amoxicillin/clavulanic acid which, after careful review of the medical record, it was found he had tolerated without issue previously. The patient was instructed to complete a 14-day antibiotic course and follow up with podiatry and his primary care physician (PCP).

Following discharge, the patient subsequently returned to the emergency department less than 24 hours later with complaints of worsening pain as well as increased erythema in the right lower extremity (Figure 2) and was found to have mild leukocytosis (white blood cell count 12.3) for the first time since his initial presentation prior to operative sequestrectomy. The patient was readmitted and antibiotics were switched to cefepime and vancomycin. Intraoperative culture from the initial hospitalization subsequently resulted with Alcaligenes faecalis on postoperative day four, identified by matrix-assisted laser desorption/ionization with time of flight and mass spectrometry (MALDI-TOF MS), consistent with previous Gram stain features. The Infectious Disease service was consulted and the patient was switched to oral amoxicillin/clavulanic acid with oral TMP-SMX after the cultured Alcaligenes faecalis was found to be sensitive to the latter (Table 1). Of note, the isolated A. faecalis had only intermediate sensitivity to piperacillin/tazobactam. Following clinical improvement and resolution of leukocytosis on this antibiotic regimen, the patient was discharged with appropriate follow-up. Approximately two weeks following discharge, the patient remained without systemic signs of infection on an office visit with his PCP.

Antibiotic Interpretation MIC (µg/mL)
Ciprofloxacin S 1
Gentamicin S 4
Levofloxacin S 1
Piperacillin + Tazobactam I 64
Tobramycin S 2
Trimethoprim + Sulfamethoxazole  S <=20


A. faecalis bacteria is usually considered non-pathogenic and has even been proposed as a potential probiotic [7]. Opportunistic infections due to A. feacalis do occur in humans [8]; however, previous cases of A. faecalis osteomyelitis have only been rarely reported. Skin and soft tissue infections of A. faecalis, including infections associated with diabetic foot ulcers, have been previously described; however, to the authors’ knowledge, only three other cases of A. faecalis osteomyelitis have been reported, all three in patients with diabetic foot ulcers [5,6]

A. faecalis is typically associated with opportunistic infections; however, it has also been associated with significant antimicrobial resistance. Organisms that are resistant to all commercially available antimicrobials are considered pandrug-resistant (PDR). Although unusual, PDR bloodstream infections of A. faecalis species have been recently reported [9]. In the present case, the patient experienced an acute clinical worsening after being transitioned from broad-spectrum empiric antibiotics to a more focused antimicrobial regime of amoxicillin/clavulanic acid to which his Streptococcus pyogenes infection was shown to be sensitive. After adding TMP-SMX, an antibiotic to which this particular A. faecalis isolate was susceptible, he clinically improved and continued to do well several weeks following discharge. Unfortunately, data for the A. faecalis sensitivity to amoxicillin/clavulanic acid was not obtained. 

The literature shows only a few cases of A. faecalis osteomyelitis, which have all occurred in cases of diabetic foot ulcer infection. Of the reported cases of A. faecalis osteomyelitis, one was sensitive to all tested antibiotics while the other had only intermediate sensitivity to piperacillin/tazobactam and amoxicillin/clavulanic acid and was deemed to have extensive drug resistance by the authors [6]. More generally, previously documented cases of A. faecalis have been successfully treated with amoxicillin/clavulanic acid [5,10]; however, more recently a case of a patient with extended-spectrum β-lactamase (ESBL)-producing A. faecalis infection has been reported [11]. In a sample of 188 patients with chronic suppurative otitis media, A. faecalis was always susceptible to aminoglycosides amikacin, cephalosporins, and colistin and usually susceptible to gentamicin, tobramycin, and piperacillin/tazobactam (90% susceptibility), with good susceptibility (75%) to TMP-SMX [12]. However, a more recent study of 61 patients showed the best sensitivity rate to A. faecalis was 66.7% for three antibiotics (imipenem, meropenem, and ceftazidime) with two antibiotics (ciprofloxacin and piperacillin/tazobactam) sensitivity rates less than 50% [2]. A recent case study of cavitary pneumonia reported complete resistance to all antibiotics available commercially [13]. Recent empiric treatment recommendations for A. faecalis include the use of piperacillin-tazobactam, TMP-SMX, meropenem, and ceftazidime with minocycline as an alternative treatment option [14].


Diabetic foot ulcers with A. faecalis infection have been occasionally reported in the literature; however, A. faecalis has been only rarely associated with osteomyelitis. We have presented another case of A. faecalis associated osteomyelitis with antibiotic resistance beyond what has been previously reported as typical for A. faecalis. Antibiotic resistance has been highlighted in the recent literature regarding A. faecalis. In this setting, optimal treatment of diabetic foot ulcers is important in minimizing comorbidities and the need for more invasive interventions including limb amputation and/or antimicrobials; when required, definitive antibiotic therapy for A. faecalis should consider the propensity for antimicrobial resistance in A. faecalis and should be promptly initiated based on culture results and susceptibility data.


  1. Singha LP, Kotoky R, Pandey P: Draft genome sequence of Alcaligenes faecalis BDB4, a polyaromatic hydrocarbon-degrading bacterium isolated from crude oil-contaminated soil. Genome Announc. 2017, 5:10.1128/genomeA.01346-17
  2. Huang C: Extensively drug-resistant Alcaligenes faecalis infection. BMC Infect Dis. 2020, 20:833. 10.1186/s12879-020-05557-8
  3. Wisplinghoff H: Pseudomonas spp., Acinetobacter spp. and miscellaneous Gram-negative bacilli. Infectious Diseases (Fourth Edition). Jonathan Cohen, William G. Powderly, and Steven M. Opal (ed): Elsevier, Amsterdam; 2017. 2:1579-99. 10.1016/B978-0-7020-6285-8.00181-7
  4. Lang J, Li Y, Yang W, et al.: Genomic and resistome analysis of Alcaligenes faecalis strain PGB1 by Nanopore MinION and Illumina technologies. BMC Genomics. 2022, 23:316. 10.1186/s12864-022-08507-7
  5. Tena D, Fernández C, Lago MR: Alcaligenes faecalis: an unusual cause of skin and soft tissue infection. Jpn J Infect Dis. 2015, 68:128-30. 10.7883/yoken.JJID.2014.164
  6. Huang C: Diabetic foot ulcer with Alcaligenes faecalis infection. Dubai Diabetes and Endocrinology Journal. 2020, 26:128-33. 10.1159/000508094
  7. Basharat Z, Yasmin A, He T, Tong Y: Genome sequencing and analysis of Alcaligenes faecalis subsp. phenolicus MB207. Sci Rep. 2018, 8:3616. 10.1038/s41598-018-21919-4
  8. Gutiérrez-Falcón AI, Ramos-Nuez AM, de Los Monteros Y Zayas AE, et al.: Probiotic properties of Alcaligenes faecalis isolated from Argyrosomus regius in experimental peritonitis (rat model). Probiotics Antimicrob Proteins. 2021, 13:1326-37. 10.1007/s12602-021-09767-7
  9. Hasan MJ, Nizhu LN, Rabbani R: Bloodstream infection with pandrug-resistant Alcaligenes faecalis treated with double-dose of tigecycline. IDCases. 2019, 18:e00600. 10.1016/j.idcr.2019.e00600
  10. Bizet J, Bizet C: Strains of Alcaligenes faecalis from clinical material. J Infect. 1997, 35:167-9. 10.1016/s0163-4453(97)91710-2
  11. Puah SM, Puthucheary SD, Chua KH: First report of extended-spectrum β-lactamases TEM-116 and OXA-10 in clinical isolates of Alcaligenes species from Kuala Lumpur, Malaysia. Jpn J Infect Dis. 2019, 72:266-9. 10.7883/yoken.JJID.2018.031
  12. Filipe M, Reimer Å, Matuschek E, Paul M, Pelkonen T, Riesbeck K: Fluoroquinolone-resistant Alcaligenes faecalis related to chronic suppurative otitis media, Angola. Emerg Infect Dis. 2017, 23:1740-2. 10.3201/eid2310.170268
  13. Al-Zakhari R, Suhail M, Ataallah B, Aljammali S, Grigos A: Rare but fatal case of cavitary pneumonia caused by Alcaligenes faecalis. Cureus. 2020, 12:e8934. 10.7759/cureus.8934
  14. Spencer HK, Spitznogle SL, Borjan J, Aitken SL: An overview of the treatment of less common non-lactose-fermenting Gram-negative bacteria. Pharmacotherapy. 2020, 40:936-51. 10.1002/phar.2447

Case report

Right Lower Extremity Osteomyelitis With Alcaligenes faecalis in a Patient With Poorly Controlled Type 2 Diabetes Mellitus

Author Information

John C. Smith Corresponding Author

Division of Internal Medicine, Kettering Health, Dayton, USA

Marco Comianos

Division of Internal Medicine, Kettering Health, Dayton, USA

Wesley Tang

Division of Internal Medicine, Kettering Health, Dayton, USA

Satish Sarvepalli

Division of Infectious Disease, Kettering Health, Dayton, USA

Division of Infectious Disease, South Dayton Acute Care Consultants, Dayton, USA

Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Case report

Right Lower Extremity Osteomyelitis With Alcaligenes faecalis in a Patient With Poorly Controlled Type 2 Diabetes Mellitus

Figures etc.


Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.